Copyright Reports & Markets. All rights reserved.

Global Intravenous (IV) Iron Drugs Market Research Report 2021

Request for Sample of this report
Buy now

1 Intravenous (IV) Iron Drugs Market Overview

  • 1.1 Product Overview and Scope of Intravenous (IV) Iron Drugs
  • 1.2 Intravenous (IV) Iron Drugs Segment by Type
    • 1.2.1 Global Intravenous (IV) Iron Drugs Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Ferric Carboxymaltose
    • 1.2.3 Iron Sucrose
    • 1.2.4 Iron Dextran
    • 1.2.5 Others
  • 1.3 Intravenous (IV) Iron Drugs Segment by Application
    • 1.3.1 Intravenous (IV) Iron Drugs Sales Comparison by Application: (2021-2027)
    • 1.3.2 Nephrology
    • 1.3.3 Gynecology & Obstetrics
    • 1.3.4 Gastroenterology
    • 1.3.5 Oncology
    • 1.3.6 Cardiology
    • 1.3.7 Others
  • 1.4 Global Intravenous (IV) Iron Drugs Market Size Estimates and Forecasts
    • 1.4.1 Global Intravenous (IV) Iron Drugs Revenue 2016-2027
    • 1.4.2 Global Intravenous (IV) Iron Drugs Sales 2016-2027
    • 1.4.3 Intravenous (IV) Iron Drugs Market Size by Region: 2016 Versus 2021 Versus 2027

2 Intravenous (IV) Iron Drugs Market Competition by Manufacturers

  • 2.1 Global Intravenous (IV) Iron Drugs Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Intravenous (IV) Iron Drugs Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Intravenous (IV) Iron Drugs Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Intravenous (IV) Iron Drugs Manufacturing Sites, Area Served, Product Type
  • 2.5 Intravenous (IV) Iron Drugs Market Competitive Situation and Trends
    • 2.5.1 Intravenous (IV) Iron Drugs Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Intravenous (IV) Iron Drugs Players Market Share by Revenue
    • 2.5.3 Global Intravenous (IV) Iron Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Intravenous (IV) Iron Drugs Retrospective Market Scenario by Region

  • 3.1 Global Intravenous (IV) Iron Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Intravenous (IV) Iron Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Intravenous (IV) Iron Drugs Market Facts & Figures by Country
    • 3.3.1 North America Intravenous (IV) Iron Drugs Sales by Country
    • 3.3.2 North America Intravenous (IV) Iron Drugs Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Intravenous (IV) Iron Drugs Market Facts & Figures by Country
    • 3.4.1 Europe Intravenous (IV) Iron Drugs Sales by Country
    • 3.4.2 Europe Intravenous (IV) Iron Drugs Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Intravenous (IV) Iron Drugs Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Intravenous (IV) Iron Drugs Sales by Region
    • 3.5.2 Asia Pacific Intravenous (IV) Iron Drugs Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Intravenous (IV) Iron Drugs Market Facts & Figures by Country
    • 3.6.1 Latin America Intravenous (IV) Iron Drugs Sales by Country
    • 3.6.2 Latin America Intravenous (IV) Iron Drugs Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Intravenous (IV) Iron Drugs Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Intravenous (IV) Iron Drugs Sales by Country
    • 3.7.2 Middle East and Africa Intravenous (IV) Iron Drugs Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Intravenous (IV) Iron Drugs Historic Market Analysis by Type

  • 4.1 Global Intravenous (IV) Iron Drugs Sales Market Share by Type (2016-2021)
  • 4.2 Global Intravenous (IV) Iron Drugs Revenue Market Share by Type (2016-2021)
  • 4.3 Global Intravenous (IV) Iron Drugs Price by Type (2016-2021)

5 Global Intravenous (IV) Iron Drugs Historic Market Analysis by Application

  • 5.1 Global Intravenous (IV) Iron Drugs Sales Market Share by Application (2016-2021)
  • 5.2 Global Intravenous (IV) Iron Drugs Revenue Market Share by Application (2016-2021)
  • 5.3 Global Intravenous (IV) Iron Drugs Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Sanofi US
    • 6.1.1 Sanofi US Corporation Information
    • 6.1.2 Sanofi US Description and Business Overview
    • 6.1.3 Sanofi US Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Sanofi US Product Portfolio
    • 6.1.5 Sanofi US Recent Developments/Updates
  • 6.2 Allergan
    • 6.2.1 Allergan Corporation Information
    • 6.2.2 Allergan Description and Business Overview
    • 6.2.3 Allergan Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Allergan Product Portfolio
    • 6.2.5 Allergan Recent Developments/Updates
  • 6.3 AMAG Pharmaceuticals
    • 6.3.1 AMAG Pharmaceuticals Corporation Information
    • 6.3.2 AMAG Pharmaceuticals Description and Business Overview
    • 6.3.3 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 AMAG Pharmaceuticals Product Portfolio
    • 6.3.5 AMAG Pharmaceuticals Recent Developments/Updates
  • 6.4 Dalichi Sankyo
    • 6.4.1 Dalichi Sankyo Corporation Information
    • 6.4.2 Dalichi Sankyo Description and Business Overview
    • 6.4.3 Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Dalichi Sankyo Product Portfolio
    • 6.4.5 Dalichi Sankyo Recent Developments/Updates
  • 6.5 Luitpold Pharmaceuticals
    • 6.5.1 Luitpold Pharmaceuticals Corporation Information
    • 6.5.2 Luitpold Pharmaceuticals Description and Business Overview
    • 6.5.3 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Luitpold Pharmaceuticals Product Portfolio
    • 6.5.5 Luitpold Pharmaceuticals Recent Developments/Updates
  • 6.6 Pharmacosmos
    • 6.6.1 Pharmacosmos Corporation Information
    • 6.6.2 Pharmacosmos Description and Business Overview
    • 6.6.3 Pharmacosmos Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Pharmacosmos Product Portfolio
    • 6.6.5 Pharmacosmos Recent Developments/Updates
  • 6.7 Takeda Pharmaceutical
    • 6.6.1 Takeda Pharmaceutical Corporation Information
    • 6.6.2 Takeda Pharmaceutical Description and Business Overview
    • 6.6.3 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Takeda Pharmaceutical Product Portfolio
    • 6.7.5 Takeda Pharmaceutical Recent Developments/Updates

7 Intravenous (IV) Iron Drugs Manufacturing Cost Analysis

  • 7.1 Intravenous (IV) Iron Drugs Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Intravenous (IV) Iron Drugs
  • 7.4 Intravenous (IV) Iron Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Intravenous (IV) Iron Drugs Distributors List
  • 8.3 Intravenous (IV) Iron Drugs Customers

9 Intravenous (IV) Iron Drugs Market Dynamics

  • 9.1 Intravenous (IV) Iron Drugs Industry Trends
  • 9.2 Intravenous (IV) Iron Drugs Growth Drivers
  • 9.3 Intravenous (IV) Iron Drugs Market Challenges
  • 9.4 Intravenous (IV) Iron Drugs Market Restraints

10 Global Market Forecast

  • 10.1 Intravenous (IV) Iron Drugs Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Intravenous (IV) Iron Drugs by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Intravenous (IV) Iron Drugs by Type (2022-2027)
  • 10.2 Intravenous (IV) Iron Drugs Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Intravenous (IV) Iron Drugs by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Intravenous (IV) Iron Drugs by Application (2022-2027)
  • 10.3 Intravenous (IV) Iron Drugs Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Intravenous (IV) Iron Drugs by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Intravenous (IV) Iron Drugs by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Ferric Carboxymaltose
    Iron Sucrose
    Iron Dextran
    Others

    Segment by Application
    Nephrology
    Gynecology & Obstetrics
    Gastroenterology
    Oncology
    Cardiology
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    By Company
    Sanofi US
    Allergan
    AMAG Pharmaceuticals
    Dalichi Sankyo
    Luitpold Pharmaceuticals
    Pharmacosmos
    Takeda Pharmaceutical

    Buy now